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Abstract: Objective: The objective of this systematic review is to summarize the literature to date on the rates of infusion 
reactions (IR) associated with chemotherapies and monoclonal antibody (mAb) drug therapies used for the treatment of 
metastatic colorectal cancer (mCRC) and the associated clinical and economic impact.  
Methods: This study searched Medline, Medline (R) In-Process, Embase and Cochrane Library databases for studies on 
IRs associated with chemotherapy and mAbs in mCRC patients from 2000-2011. 
Results: For chemotherapy, the incidence of IRs ranged from 0-71% for all grades and 0-15% for grade 3-4. Rates of all 
grade IRs associated with cetuximab ranged from 7.6-33% and grade 3-4 IR rates were 0-22%. Rates of all grade IRs 
associated with panitumumab ranged from 0-4% and rates of grade 3-4 IRs ranged from 0-1%. The overall rate of IRs 
associated with bevacizumab ranged from 1.6-11%, with a rate of 0-4% for grade 3-4 IRs. A range of 50-100% of patients 
with grade 3-4 IRs terminated chemotherapy, and 34-100% of cetuximab patients with grade 3-4 IRs discontinued 
cetuximab therapy. No data were reported for bevacizumab or panitumumab. Only one study evaluated the economic 
impact of IRs. The study compared cetuximab administrations without an IR to those with an IR requiring resource 
utilization and found that mean costs were $9308 and $1725 higher for those with an IR requiring an emergency room 
visit or hospitalization and for those with an IR requiring outpatient treatment, respectively.  
Conclusions: The incidence of IRs varies among different mAbs; and IRs may cause treatment disruption and require 
costly medical interventions.  
Presentation: A portion of the manuscript was presented as a poster (PCN20) at the International Society for Pharma- 
coeconomics and Outcomes Research (ISPOR) 15th Annual International Meeting 2010 in Atlanta, Georgia, USA. 
Keywords: Chemotherapy, costs, infusion reaction, metastatic colorectal cancer, monoclonal antibody drugs, resource utilization.  
INTRODUCTION 
  Colorectal cancer (CRC) is the third most frequently 
diagnosed cancer and the third leading cause of cancer   
death in the USA. According to estimates based on the 
Surveillance, Epidemiology and End Results (SEER) 
database, about 20% of patients with CRC are diagnosed 
with metastasis [1], and 50% of patients treated for early 
stage CRC will eventually develop metastases [2]. The 5-
year survival rate for patients with metastatic CRC (mCRC) 
is about 10% [1]. In Europe, CRC is the second most 
common form of cancer and also the second leading cause of 
death from cancer [3]. 
  Recent advances in molecular oncology and an enhanced 
understanding of tumor cell signaling pathways have   
led to new targeted biologic therapies for mCRC that   
have translated into improvements in patient outcomes. 
Among the new agents are three monoclonal antibody (mAb)  
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drugs: bevacizumab, a humanized mAb targeting vascular 
endothelial growth factor (VEGF); cetuximab and 
panitumumab, both targeting epidermal growth factor 
receptors (EGFR) with cetuximab being a chimeric while 
panitumumab being a fully human mAb. Progress   
towards improved outcomes is still ongoing. For example, 
identification of wild-type KRAS tumor status as a bio- 
marker for benefit from anti-EGFR agents (cetuximab   
and panitumumab) represents an important step towards 
personalized treatment of mCRC [4-7]. 
  Infusion reactions (IRs) have been documented with 
chemotherapies and mAbs that are administered 
intravenously [8,9]. The mechanism of IRs is not clearly 
understood and may vary between agents [8]. Chung and 
colleagues have showed that in most patients experiencing 
severe IRs to cetuximab, immunoglobulin E (IgE) antibodies 
against cetuximab were present in serum before therapy and 
the antibodies were specific for galactose--1,3-galactose 
[10]. Thus, it is important to realize that IRs can be both  
non-IgE-mediated and IgE-mediated reactions, and they   
are difficult to discriminate based on clinical presentation 
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  According to the National Cancer Institute Common 
Toxicity Criteria for Adverse Events v3.0 [12], grade 1 
reactions generally do not require infusion interruption or 
intervention; grade 2 reactions are often managed by 
supportive therapy, infusion interruption or symptomatic 
treatment.
 High grade (3 or higher) IRs can be prolonged and 
may not respond rapidly to symptomatic medications, and 
can result in hospital events that require supportive patient 
care [13-15]. High grade symptoms include urticaria, nausea, 
vomiting, pruritus, bronchospasm, dyspnea and tongue 
swelling, which may progress to hypotension, respiratory 
arrest, and occasionally death. Although rare, deaths have 
resulted from severe IRs [14,16].  
  The objective of this systematic review is to summarize 
the literature to date on the rates of IRs associated with 
chemotherapies and mAb therapies used for the treatment of 
mCRC, and resource utilization and cost burden of IRs.  
METHODS 
  This systematic search strategy was designed to identify 
studies (randomized controlled trials, prospective and 
retrospective studies), and systematic reviews reporting   
IRs. Systematic searches of the Medline, Medline (R) In-
Process, Embase and Cochrane Library databases were 
performed to identify relevant articles published in English 
between 2000 and 2011. Non-systematic reviews, case 
reports, research briefs, letters, editorials, studies in animals 
and phase I and IIa studies were excluded. The systematic 
search was global in nature and was not restricted to specific 
countries. 
  Search terms included ‘infusion reaction’, ‘allergic 
reaction’, ‘hypersensitivity’, and ‘anaphylaxis’ combined with 
terms to identify articles relating to advanced or metastatic 
CRC. Treatments of interest included were fluorouracil, 
bevacizumab, irinotecan, oxaliplatin, cetuximab, panitumumab, 
capecitabine and regimens composed of combinations of 
these therapies. Pro-drugs were not considered treatments of 
interest. Articles in the following categories were excluded: 
cancers other than colorectal, non-advanced or metastatic 
cancer, adverse events not indicative of an IR, not treatment 
of interest, and study of other topics.  
RESULTS 
  The initial systematic searches of the literature retrieved 
6502 studies. After excluding duplicate articles and the 
removal of obviously irrelevant records, such as those for 
other cancers than mCRC, 733 studies remained for more 
detailed assessment. Following the first pass categorization, 
196 studies were selected for further assessment. Only 14 
records were rejected during the second pass categorization; 
182 records went for abstract review. The abstract review 
excluded 37 records, leaving 145 studies for full article 
review. A further 70 records were rejected, which led to 74 
articles for data extraction. An additional three studies were 
identified in a manual literature search. Consequently, there 
were a total of 77 studies that met all review criteria for   
the entire IR systematic review. Of these 77 studies, 
approximately 69% (53/77) of studies were prospective and 
31% (24/77) were retrospective in nature; and 39 of them 
included monoclonal biologic therapies.  
INCIDENCE RATES OF IRS 
  Package inserts and the 33 studies that report rates   
of IRs associated with chemotherapies, bevacizumab, 
cetuximab and panitumumab, are summarized in Table 1. 
For chemotherapy treatments, the incidence of all grade IRs 
ranged from 0-71%; for grade 3-4 IRs the ranges were 0-
15% [17-22]. The incidence of IRs was highest in regimens 
which included oxaliplatin. Few of the studies attributed the 
IRs to one particular drug.  
  The incidence of IRs varies with the different mAbs 
(alone or with combination of chemotherapy), and in clinical 
trials and non-clinical trials [49]. 
Bevacizumab 
  The overall rate (all grades) of IRs associated with the 
first infusion of bevacizumab, as described in the package 




  Tol and his colleagues conducted two phase III clinical 
trials in patients with mCRC treated with capecitabine, 
oxaliplatin and bevacizumab, with and without cetuximab. 
The 2008 clinical trial reported an overall IR rate of 11% and 
3% grade 3-4 IRs in patients treated with capecitabine, 
oxaliplatin, and bevacizumab (without cetuximab) and in 
those patients received cetuximab the overall IR rate and 
grade 3-4 IR rate was 23% and 7%, respectively [24]. In the 
2009 clinical trial, grade 3-4 IRs occurred in 4% of patients 
treated without cetuximab and 4.9% in those treated with 
cetuximab [25]. It is worth noting that all pivotal clinical 
trials for bevacizumab do not report information on IRs   
[50-52].  
Non-Clinical Trials 
  Schwartzberg and colleagues retrospectively reviewed 
the charts from 19 community oncology centers to identify 
patients who had received mAb treatment either as mono- 
therapy or in combination with chemotherapy, and who had 
documented evidence of a severe IR during therapy [14]. Of 
76 identified IRs (total number of charts reviewed was not 
reported), five patients who had been treated with bevacizumab 
experienced infusion reactions, and all five were grade 3 
reactions. However, the study was not designed to assess the 
incidence rate of mAb-related IRs, but rather to descriptively 
study the clinical care associated with the events.  
  Computerized pharmacy records were used to identify all 
patients who received bevacizumab at one cancer center in a 
study by Reidy et al., [26]. The center's adverse drug 
reaction reporting program was then used to identify any IRs 
related to bevacizumab with subsequent confirmation by 
medical record review. Six patients (1.6%) experienced 
minor IRs, five of whom were being treated for CRC (four 
with mCRC). No patients experienced severe IRs in that 
study.  
Cetuximab  
  As described in the package insert of cetuximab,   
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Table 1.  IR Rates Reported in Published Studies  
Study  Year  Study Design: Treatment  Number of Patients  Overall IR Rate  Severe IR Rate 
Chemotherapy 
Boige et al., [22]  2008  Prospective: FOLFOX  44  23%  9% 
Hsuen et al., [19]  2003  Retrospective: FOLFOX4  47  11%  11% 
Ichikawa et al., [18]  2009 





Li et al., [21]  2010  Phase II trial: XELOX  124  10.5%  0% 
Neyns et al., [20]  2006 
Prospective: oxaliplatin and  
L-folinic acid-modulated 5-fluorouracil 
9 11%  11% 
Suenaga et al., [17]  2008 
Retrospective analysis of a single  
institution: FOLFIRI, FOLFOX4 




2009     <3%  0.2% 
Clinical Trials 
Tol et al., [24]  2008 
Phase III trial: capecitabine, 
oxaliplatin and bevacizumab 
197 11%  3% 
Tol et al., [25]  2009 
Phase III trial: capecitabine, 
oxaliplatin and bevacizumab 
366 Not  reported  4% 
Non-Clinical Trials 
Reidy et al., [26]  2007 
Retrospective observational: bevacizumab at 
5mg/kg over 10 minutes 




2009     15-21%  2-5% 
Clinical Trials 
Cartwright et al., [28]   2008 
Phase II trial : cetuximab with capecitabine 
and irinotecan 
69 Not  reported  4% 
Cunningham et al., [29]  2004  Phase II trial: cetuximab monotherapy  115  Not reported  3.5% 
Cunningham et al., [29]  2004  Phase II trial: cetuximab with irinotecan  212  Not reported  0% 
Folprecht et al., [30]  2006 
Phase I/II: cetuximab with irinotecan/low 
dose 5-FU/folinic acid 
6 33%  0% 
Folprecht et al., [30]  2006 
Phase I/II: cetuximab with irinotecan/high 
dose 5-FU/folinic acid 
15 13%  0% 
Jonker et al., [31]  2007 
Phase III trial: cetuximab with best  
supportive care 
287 20.5%  4.5% 
Lenz et al., [32]  2006  Phase II trial: cetuximab  346  7.6%  1.7% 
Ocvirk et al., [33]  2010  Phase II trial: cetuximab with FOLFOX6  77  Not reported  6% 
Ocvirk et al., [33]  2010  Phase II trial: cetuximab with FOLFIRI  74  Not reported  1% 
Saltz et al., [34]  2004  Phase II trial: cetuximab  57  Not reported  5% 
Saltz et al., [35]  2007 
Phase II trial: cetuximab, bevacizumab,  
and irinotecan 
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Table 1. contd…. 
Study  Year  Study Design: Treatment  Number of Patients  Overall IR Rate  Severe IR Rate 
Saltz et al., [35]  2007 
Phase II trial: cetuximab and  
bevacizumab, alone 
40 Not  reported  0% 
Sobrero et al., [36]  2008  Phase III trial: cetuximab with irinotecan 648  Not  reported  1.4% 
Soulgoulakos et al., 
[37] 
2007 
Phase II trial: cetuximab with capecitabine 
and oxaliplatin 
40 15%  2.5% 
Wierzbicki et al., [38]  2011  Phase II trial: cetuximab  85  Not reported  1.2% 
Non-Clinical Trial 
Bachet et al., [39]  2007 
Retrospective record based: cetuximab with 
or without irinotecan, FOLFIRI 
105 Not  reported  6.6% 
Foley et al., [40]   2010 
Large US national claims data: cetuximab 
with and without chemotherapy 
1122 
8.4% 
(requiring medical intervention) 
George et al., [41]  2010 
Retrospective cohort: cetuximab with or 
without chemotherapy 
30 27%  17% 
O'Neil et al., [42]  2007 
Retrospective clinical record review: 
cetuximab with unspecified chemotherapy 
88 28%  22% 
Schwartzberg et al., 
[15] 
2009 
Prospective multi-center time and motion 
study: cetuximab 
71 32%  7% 
Bevacizumab +  
cetuxmiab 
Tol et al., [24]   2008 
Phase III trial: capecitabine, 
oxaliplatin and bevacizumab with cetuximab 
192 23%  7% 
Tol et al., [25]   2009 
Phase III trial: capecitabine, 
oxaliplatin and bevacizumab with cetuximab 




2010     4%  1% 
Clinical Trials 
Berlin et al., [44]  2007  Phase II trial: panitumumab with IFL  19  0%  0% 
Berlin et al., [44]  2007  Phase II trial: panitumumab with FOLFIRI  24  0%  0% 
Douillard et al., [6]  2010 
Phase III trial: panitumumab with 
FOLFOX4 
322 Not  reported  0.6% 




Muro et al., [46]  2009  Phase II trial: panitumumab  52  0%  0% 
Peeters et al., [7]  2010  Phase III trial: panitumumab with FOLFIRI  539  Not reported  0.4% 
Van Cutsem et al., [47]  2007 
Phase III trial: panitumumab with best  
supportive care 
229 0.4%  0% 
Van Cutsem et al., [48]  2008  Phase III trial: panitumumab  176  0.6%  0% 
IR, infusion reaction; CAPOX, capecitabine + oxaliplatin; ILF: irinotecan, bolus 5-FU, and leucovorin; FOLFIRI, infusional 5-FU/LV + irinotecan; FOLFOX4, 5-FU/LV + 
oxaliplatin; mFOLFOX6, modified FOLFOX6; IRINOX, irinotecan + oxaliplatin; XELIRI, Xelox (capecitabine) + irinotecan; XELOX, Xeloda (capecitabine) + oxaliplatin. 
bronchospasm, angioedema, urticaria, hypertension and 
hypotension occurred in 15-21% of patients across studies 
[27]. Grade 3 and 4 IRs occurred in 2-5% of patients, and 
fatal outcomes associated with IRs were rare (<1 in 1000) 
[27]. Clinical trials found an overall rate of IRs that ranged 
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0-6%. Observational studies found an overall rate of IRs 
from 27-32%, and the rate of grade 3-4 IRs from 6.6-22%. 
Clinical Trials 
  In a large randomized phase III trial of cetuximab plus 
best supportive care (n=287) versus best supportive care 
alone (n=285) for the treatment of patients with 
chemorefractory mCRC, all grades of IRs occurred in 20.5% 
of patients, and grade 3-4 IRs occurred in 4.5% of patients 
assigned to cetuximab. No patients randomized to best 
supportive care had any IRs [31].
  In a large, randomized, 
open-label, multicenter study (n=1198) comparing 14-day 
cycles of cetuximab plus FOLFIRI and FOLFIRI alone, 
grade 3 or 4 infusion-related reactions were more frequent 
with cetuximab plus FOLFIRI than with FOLFIRI alone (2.5% 
vs 0%, p<0.001) [4]. In a multicenter, open-label, phase III 
study of patients with mCRC, Sobrero et al., found that grade 3-
4 IRs occurred to 1.4% of patients treated with cetuximab 
and 0.8% of those on irinotecan alone (n=648) [36].
  
  In an open-label, randomized, multicenter phase II study 
comparing the efficacy and safety of cetuximab combined 
with FOLFOX4 versus FOLFOX4 alone in the first-line 
treatment of EGFR-expressing mCRC, 5% of patients treated 
with cetuximab + FOLFOX4 experienced grade 3 or 4 
infusion-related reactions compared to 2% of patients treated 
with FOLFOX4 alone [53]. 
  In a randomized phase II trial of cetuximab (with or 
without irinotecan) in 327 patients whose disease had 
progressed during or within 3 months after treatment with an 
irinotecan-based regimen, Cunningham and colleagues 
reported that 3.5% of patients on cetuximab monotherapy 
but no patients on cetuximab with irinotecan experienced 
severe IRs (grade 3 or 4) [29].  
  Additionally, five phase II clinical trials reported 
incidence rates of grade 3-4 IRs from 1-5% in patients with 
mCRC treated with cetuximab alone or cetuximab in 
combination with chemotherapies [28,32-34,38]. 
Non-Clinical Trials 
  Schwartzberg's retrospective chart review identified 
patients who had received cetuximab either as monotherapy 
or in combination with chemotherapy, and who had 
documented evidence of a severe IR during therapy [14].   
Of 76 identified IRs, 24 occurred in patients receiving 
cetuximab- 58% were grade 3, 33% grade 4, and 8% died 
before transport to hospital emergency care. Another 
Schwartzberg et al., study found that 32% of patients treated 
with cetuximab experienced grade 1 or 2 IRs, and 7% 
experienced grade 3-4 IRs [15].
  
  Interestingly, one study based on a retrospective clinical 
review reported that rates of severe IRs are much higher in 
North Carolina and Tennessee. O'Neill and colleagues 
analyzed data from the records of 88 patients with a variety 
of tumor types (39 with CRC) who were treated with 
cetuximab in clinical trials in these two states. That analysis 
found an overall rate of 28% for all grade IRs and 22% for 
grades 3-4 IRs associated with cetuximab treatment [42].  
  Using a large national retrospective claims database, 
Foley et al., identified 1122 patients with CRC treated with 
cetuximab in the period 2004-2006. Among them, 8.4% 
developed IRs that required medical intervention like 
emergency room (ER) visits, hospitalization or outpatient 
treatment [40].  
Clinical Trials on Bevacizumab and Cetuximab 
Combination Therapy 
  Three clinical trials included patients treated with both 
bevacizumab and cetuximab. A phase II clinical trial (n=83) 
by Saltz et al., found a 0% IR rate of grade 3 attributable to 
cetuximab [35], a phase III clinical trial (n=192) by Tol et 
al., found a 23% of all grade IRs and 7% of grade 3-4 IRs 
[24], and another phase III clinical trial (n=366) by Tol et al., 
found a 4.9% of grade 3-4 IRs [25]. No separate rates of IRs 
were reported for bevacizumab and cetuximab in the two 
clinical trials conducted by Tol et al., for patients treated 
with both bevacizumab and cetuximab.  
Panitumumab  
  According to the panitumumab product insert, 4% of 
patients experienced IRs, and grade 3-4 IRs occurred in 
approximately 1% of all patients [43]. Clinical trials found a 
rate of grade 3-4 IRs of 0-0.7%. There were no non-clinical 
trials that reported the IR rate of panitumumab. 
Clinical Trials 
  Van Cutsem and colleagues conducted a large, 
multicenter, randomized phase III clinical trial of 
panitumumab plus best supportive care (n=231) versus best 
supportive care alone (n=232) for the treatment of patients 
with chemorefractory mCRC. No patients experienced grade 
3-4 IRs in patients receiving panitumumab plus best 
supportive care or in patients receiving best supportive care 
alone [47]. 
  In a large, open-label, multicenter, phase III clinical trial 
that compared the efficacy of panitumumab + FOLFOX4 
with FOLFOX4 alone in patients with previously untreated 
mCRC, 0.6% (two out of 322 patients) of patients treated 
with panitumumab + FOLFOX4 had grade 3 IRs (no grade 4 
IRs) versus 0% in those treated with FOLFOX4 alone [6]. A 
similar finding was observed for panitumumab in second-
line treatment of mCRC. Peeters et al., assessed the safety 
and efficacy of panitumumab + FOLFIRI versus FOLFIRI 
alone in a large, open-label, multicenter, phase III clinical 
trial, grade 3-4 IRs were seen in 0.7% and 0% in patients 
treated with panitumumab + FOLFIRI and those treated with 
FOLFIRI alone, respectively [7]. Additionally, an overall IR 
rate of 0-0.7% was also in four phase II clinical trials [44-
46,48].  
CLINICAL AND ECONOMIC IMPACT OF IRS 
  The occurrence and management of severe or mild IRs 
can have significant clinical and economic impact on 
patients, caregivers, and oncology practices, particularly 




  Treatment interruption or discontinuation may be 
required for patients experiencing IRs. This has significant 
implications for mCRC treatment because in many cases Systematic Review on Infusion Reactions Associated with Chemotherapies  Current Clinical Pharmacology, 2012, Vol. 7, No. 1    61 
mAbs are administered to patients whose disease has 
progressed following chemotherapy and, therefore, had 
limited treatment options.  
  A total of 16 studies reported treatment termination due 
to severe IRs. Treatment was terminated in the majority of 
patients who experienced grade 3 or 4 IRs in these studies. 
There were only six studies that reported that some patients 
remained on treatment after a grade 3 or 4 IR [14,18,35, 
40,53,56]
 (Table 2).  
  Eight studies reported discontinuation of cetuximab due 
to severe IRs. Among the three patients who developed 
cetuximab-related grade 3 IRs in a phase II study by Saltz et 
al., two discontinued cetuximab [35]. In the Foley et al., 
study, 68% of cetuximab patients with any IRs requiring 
medical intervention experienced treatment interruption, of 
which 34% permanently discontinued cetuximab. For 
patients who experienced IRs that required emergency room 
visits or hospitalization, 53% discontinued cetuximab 
permanently [40]. In the George et al., study, all patients 
with severe IRs discontinued cetuximab permanently, with 
80% of them switching to panitumumab [41]. In a phase II 
clinical trial on patients with mCRC treated with cetuximab 
plus capecitabine/irinotecan, all patients with grade 3-4 IRs 
discontinued treatment [28]. Across all seven cetuximab 
studies included in Table 3, 34-100% of cetuximab users 
who experienced grade 3-4 IRs terminated cetuximab 
treatment. There were four studies that reported that some 
patients remained on cetuximab after a grade 3 or 4 IR 
[14,35,40,53]. 
  Schwartzberg and colleagues’ study is the only one that 
reported treatment disruption with IRs associated with 
bevacizumab. Three out of the five patients who experienced 
severe IRs permanently discontinued bevacizumab treatment 
during this study [14].  
  No studies reporting treatment termination involving 
panitumumab were identified. In a phase II clinical trial, one 
out of 148 panitumumab users developed a severe IR after 
the second panitumumab infusion [45]. That reaction was 
Table 2.  Studies with Reported Treatment Terminations as a Result of Severe Infusion Reactions 




among those with IRs (%) 
Chemotherapy 
Becouarn et al., [57]  2007 Grade  4  IRINOX 3%  100% 
Desai et al., [58]  2005  Grade 3  Cyclosporine, irinotecan and 5-FU  6%  100% 
Hsuen et al., [19]  2003 Grade  3  FOLFOX4  11%  100% 
Ichikawa et al., [18]  2009  Grade 3-4  FOLFOX4 or Modified FOLFOX6  6%  50% 
Kalofonos et al., [59]  2006 Grade  5  FOLFOX  1%  100% 
Matsumoto et al., [56]  2008  Grade 3-4  Modified FOLFOX6  4%  60% 
Seki et al., [60]  2009 Grade  3 
5FU followed by FOLFOX4 or 
modified FOLFOX6 
5% 100% 
Shibata et al., [61]  2009 Grade  3  FOLFOX4  4%  100% 
mAbs 
Bachet et al., [39]  2007  Grade 3-4  Cetuximab  7%  100% 
Bokemeyer et al., [53]  2009  Grade 3-4  Cetuximab + FOLFOX4  5%  88% 
Cartwright et al., [28]  2008  Grade 3-4  Cetuximab + XELIRI  4%  100% 
Foley et al., [40]  2010  Grade 3-4  Cetuximab with or without chemotherapy  8%  34% 
George et al., [41]  2010  Grade 3  Cetuximab with or without chemotherapy  10%  100% 
George et al., [41]  2010  Grade 4  Cetuximab With or without chemotherapy  7%  100% 
Saltz et al., [34]  2004  Grade 3-4  Cetuximab  5%  67% 
Schwartzberg et al., [14]  2008 Grade  3-4  Cetuximab  NA  82% 
Schwartzberg et al., [14]  2008 Grade  3  Bevacizumab  NA  60% 
Sobrero et al., [36]  2008  Grade 3-4  Cetuximab + Irinotecan  1%  100% 
FOLFOX4, 5-FU/LV + oxaliplatin; mFOLFOX6, modified FOLFOX6; IRINOX, irinotecan + oxaliplatin; XELIRI, Xelox (capecitabine) + irinotecan. 62    Current Clinical Pharmacology, 2012, Vol. 7, No. 1  Song et al. 
managed with antihistamine and analgesic treatment, and the 
patient was able to continue therapy. 
 
  Many of the articles reported the modification of 
intervention dosage based on the protocol specified, but did 
not report the number of dose reductions and delayed doses 
in the final results of their studies. For cetuximab, one study 
reported dose reductions [40],
 and three studies reported dose 
delays or changes in the rate of infusion [36,40,62]. For 
panitumumab, only one study reported dose delay or changes 
because of IRs [47]. However, it is difficult to estimate the 
actual number of dose reductions and delays because of the 
paucity of specific data.  
Resource Use 
  Seven studies reported hospitalization of patients for the 
treatment of IRs [14,18,35,40,41,56,63]. The proportion of 
patients experiencing IRs who were hospitalized varied from 
7.7-39.4%. A prospective time and motion study of cancer 
patients with severe IRs in the USA found that 22% were 
hospitalized with a 4-day length of stay on average [15].
 In 
addition, patients with IRs required between 31% and 80% 
additional staff time [15]. The percentage of patients with 
CRC hospitalized for IRs associated with cetuximab 
treatment varied from 14.3-39.4% [14,35,40,41]
  (Table  3). 
No separate data exist that reported hospitalization rates for 
IRs associated with bevacizumab or panitumumab. 
Economic Impact  
  Studies that examined the economic impact of IRs are 
very limited. At the time of this review, Foley et al., was the 
only study that directly estimated the incremental healthcare 
costs associated with treatment of IRs in patients with CRC 
treated with cetuximab [40]. Using a US national claims data 
set, they estimated that the mean cost was $13,863 for 
cetuximab administrations with an IR requiring an 
emergency room visit or hospitalization and $6280 for those 
with an IR requiring outpatient treatment, compared to costs 
of $4555 for those without an IR [40].
  
Impact on Patients, Clinicians and Caregivers 
  IRs impose significant burden on patients, healthcare 
providers and caregivers. This includes psychological impact 
and burden on patients and clinicians’ attitude towards 
treatment and economic burden on patients’ families 
including out-of-pocket expenses and travel time to the 
outpatient clinic and hospital [54,55]. IRs are emotionally 
stressful and disruptive for patients and their caregivers. 
During in-person interviews of 202 oncology nurses in the 
USA, 87% reported that both patients and clinicians feel 
‘fear’ and ‘stress’ even with the occurrence of mild IRs. 
Grade 3 or 4 IRs were ‘very’ or ‘extremely’ disruptive for 
patients and disruptive to nurses 80% of the time [64]. 
O’Neil  et al.,. noted that the experience of an IR can be 
traumatic for patients, family members, and the clinical staff 
managing these events [42].  
DISCUSSION 
  Although mCRC remains incurable, the introduction of 
mAb therapies has improved patient treatment outcomes. 
However, severe IRs can occur with these treatment options 
and their management can be challenging to patients and 
clinicians.  
  This systematic review of the literature included 77 
articles on IR rates resulting from the currently available 
chemo- and mAb therapies in patients with mCRC, and the 
burden of these IRs. For chemotherapy treatments, the 
incidence of IRs ranged from 0-71% for all grades and 0-
15% for grade 3-4. The literature on cetuximab was most 
common with 17 studies published beyond those noted in the 
product’s package insert. However, there was considerable 
heterogeneity in rates of IR observed across these studies. Of 
the 17 studies, the overall rates of all IRs ranged from a low 
of 7.6% to a high of 33%, as compared to rates of 15-21% as 
noted in the cetuximab package insert. Rates of severe IRs 
(grade 3-4) ranged from a low of 0% to a high of 22% found 
by in O’Neil et al., [42]. Findings for panitumumab were 
more homogenous, but relied on fewer studies. Seven studies 
Table 3.  Infusion Reactions Requiring Hospitalization 
Author Year  Treatment  Grade  of  Reaction 
Incidence of 
Reactions 
Of Patients who had IRs,  
% whom Required Hospitalization 
Chemotherapy 
Brandi et al., [63]  2003  FOLFOX 4  All grades  18%  10% 
Ichikawa et al., [18]  2009  FOLFOX4 or modified FOLFOX6  Grade 3-4  6%  16.7% 













Foley et al., [40]  2010  Cetuximab 
IRs requiring medical 
intervention 8.4%  39.4% 
George Jr et al., [41]  2010  Cetuximab +/- chemotherapy  Grades 2-4  27%  14.3% 
Saltz et al., [35]   2004  Cetuximab  Grade 3-4  5.3%  33% 
Schwartz et al., [14]   2008  cetuximanb, bevacizumab  Grade 3 or higher  Not reported  22% Systematic Review on Infusion Reactions Associated with Chemotherapies  Current Clinical Pharmacology, 2012, Vol. 7, No. 1    63 
were available for panitumumab, with severe IRs ranging 
from 0-0.7%, compared to 1% reported in the package insert. 
Only three studies [24-26] were available for bevacizumab 
beyond the trials noted in the package insert. Reidy et al., 
reported that 1.6% of cases experienced mild IRs, similar to 
the <3% documented in the package insert data [26]. Two 
clinical trials by Tol et al., found a much higher rate of IRs 
with bevacizumab. The first study reported 11% of all grade 
IRs and 3% grade 3-4 IRs [24], and the second reported   
4% severe IRs in patients treated with bevacizumab, 
capecitabine and oxaliplatin [25].  
  Within the available literature, the rates of IR for 
panitumumab appeared relatively consistent with rates 
observed in its clinical trials (as reported in panitumumab 
package insert). Conversely, there are substantial variations 
in the incidence rates of IRs associated with cetuximab 
included in the cetuximab product insert and those reported 
in various studies. However, most of the non-clinical trials 
were small studies. Some studies have found that the 
incidence of IRs varies between US geographic regions 
[43,65]. Atopic history and residence in the middle Southern 
region of the US have been associated with high incidence of 
severe IRs [40,56]. A relationship between prior allergy 
history and IRs was also noted, suggesting a pre-existing 
IgE-based immune reaction directed at the therapeutic 
antibody [10,11]. Foley et al., found that residence in a state 
with high levels of pollen was associated with a higher 
likelihood of having an IR requiring medical intervention 
among patients with CRC treated with cetuximab [40].
 While 
the prescribing information for cetuximab indicates that 90%
 
of severe IRs occurred during the initial cetuximab 
administration, Needle reported that 33% of patients with 
severe IRs experienced events after their second dose of 
cetuximab [66].
 Lenz also noted that 10-30% of IRs to mAbs 
are delayed and occur in later infusions [9]. 
 
  There were also studies that reported findings on the 
clinical and financial impact of IRs, and many of these 
studies were related to the cetuximab treatment. In the 
majority of these studies, if patients experienced a grade 3 or 
4 IR, treatment was terminated. The rate of discontinuation 
of therapy following a severe IR ranged from 34% to 100% - 
although the sample sizes from which these rates were 
determined were small. The claims database study by Foley 
et al., found that compared to those without IRs, patients 
requiring outpatient management of an IR had approximately 
$1725 in incremental costs and those who had ER visits or 
were hospitalized due to their IRs had incremental costs of 
$9308. 
  Low grade reactions can often be managed by supportive 
therapy, infusion interruption or symptomatic treatment. 
Some patients can be re-challenged and remain on the same 
treatment after low grade reactions [9]. High grade reactions 
may demand immediate treatment interruption, modification 
or discontinuation, and can result in ER visits and hospital 
events that require supportive patient care [13-15,28,35, 
40,41].  
  Interpretation of results from this systematic review of 
the literature on IRs needs to take its limitations into 
consideration. The incidences of IR described in this review 
showed some heterogeneity among the included studies.   
This may reflect differences in definition of IRs, sample 
sizes, number of patients treated, study design, patient 
characteristics, concomitant
  chemotherapies, or many other 
factors among these studies. Particularly, most of non-
clinical trials had small sample size and the estimates of IR 
rates were less reliable; thus, the interpretation of findings 
based on those studies needs to be cautious.  
SUMMARY 
  There were relatively more published studies reporting 
IRs associated with the use of cetuximab and some of non-
clinical trials reported higher rates of IRs in patients with 
mCRC treated with cetuximab than that was listed in the 
package insert. In contrast, the rates of IRs for panitumumab 
appear to be consistent with clinical trial findings, although 
relatively fewer studies have been published. Studies to date 
have also indicated that IRs often cause treatment disruption 
and require costly medical interventions.  
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